Kailera Therapeutics secured $600 million in a Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable targeting the same receptors as existing dual‑agonist obesity drugs, into global phase 3 testing. The financing will also support other oral and injectable metabolic candidates in Kailera’s pipeline. Company statements framed the cash as enabling global trials and regulatory-readiness for a highly competitive obesity market dominated by GLP‑1/Tirzepatide‑class agents.